|

PD-1/PD-L1 inhibitors Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Chuangzhen Chen1

Indications

  • Borderline Resectable Carcinoma1
  • Unresectable Cancer1
  • Tislelizumab1
  • Immune Checkpoint Inhibitor1
  • Radiotherapy1

Other1 trial

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.